314 related articles for article (PubMed ID: 30707246)
1. A multicentre controlled pre-post trial of an implementation science intervention to improve venous thromboembolism prophylaxis in critically ill patients.
Stelfox HT; Brundin-Mather R; Soo A; Parsons Leigh J; Niven DJ; Fiest KM; Doig CJ; Zuege DJ; Kushner B; Clement F; Straus SE; Cook DJ; Bagshaw SM; Sauro KM
Intensive Care Med; 2019 Feb; 45(2):211-222. PubMed ID: 30707246
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
5. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
Jacobs BN; Cain-Nielsen AH; Jakubus JL; Mikhail JN; Fath JJ; Regenbogen SE; Hemmila MR
J Trauma Acute Care Surg; 2017 Jul; 83(1):151-158. PubMed ID: 28426561
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.
Pai M; Adhikari NKJ; Ostermann M; Heels-Ansdell D; Douketis JD; Skrobik Y; Qushmaq I; Meade M; Guyatt G; Geerts W; Walsh MW; Crowther MA; Friedrich JO; Burry L; Bellomo R; Brandão da Silva N; Costa Filho R; Cox MJ; Alves Silva S; Cook DJ;
PLoS One; 2018; 13(6):e0198285. PubMed ID: 29856817
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
8. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV
J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202
[TBL] [Abstract][Full Text] [Related]
9. Impact of thromboprophylaxis across the US acute care setting.
Huang W; Anderson FA; Rushton-Smith SK; Cohen AT
PLoS One; 2015; 10(3):e0121429. PubMed ID: 25816146
[TBL] [Abstract][Full Text] [Related]
10. Practice Patterns of Venous Thromboembolism Prophylaxis in Underweight, Critically Ill Patients with Neurologic Injury.
Betthauser K; Pope H; Gowan M; Human T
Neurocrit Care; 2017 Aug; 27(1):96-102. PubMed ID: 28097621
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically Ill patients.
Lee YR; Blanco DD
J Thromb Thrombolysis; 2017 Oct; 44(3):386-391. PubMed ID: 28828713
[TBL] [Abstract][Full Text] [Related]
12. Prevention of venous thromboembolism in critically ill medical patients: a Franco-Canadian cross-sectional study.
Lacherade JC; Cook D; Heyland D; Chrusch C; Brochard L; Brun-Buisson C;
J Crit Care; 2003 Dec; 18(4):228-37. PubMed ID: 14691896
[TBL] [Abstract][Full Text] [Related]
13. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
Trials; 2014 Dec; 15():502. PubMed ID: 25528663
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism prophylaxis in the critically ill: a point prevalence survey of current practice in Australian and New Zealand intensive care units.
Robertson MS; Nichol AD; Higgins AM; Bailey MJ; Presneill JJ; Cooper DJ; Webb SA; McArthur C; MacIsaac CM; ;
Crit Care Resusc; 2010 Mar; 12(1):9-15. PubMed ID: 20196708
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
[No Abstract] [Full Text] [Related]
18. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
[TBL] [Abstract][Full Text] [Related]
19. Hospital-based costs associated with venous thromboembolism treatment regimens.
Merli G; Ferrufino C; Lin J; Hussein M; Battleman D
J Thromb Haemost; 2008 Jul; 6(7):1077-86. PubMed ID: 18445118
[TBL] [Abstract][Full Text] [Related]
20. Determining the impact of culture on venous thromboembolism prevention in trauma patients: A Southwestern Surgical Congress Multicenter trial.
Regner JL; Shaver CN;
Am J Surg; 2019 Jun; 217(6):1030-1036. PubMed ID: 30503515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
